Fleece Bound Tissue Sealing With TachoSil® to Assist in Closing of the Dura Mater After Elective Craniotomy to Reduce Postoperative Cerebrospinal Fluid (CSF) Leakage.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 241
- 试验地点
- 2
- 主要终点
- Occurence of CSF pad or leakage needing any kind of intervention.
研究概览
简要总结
Main objective of this trial is to assess the hypothesis whether the application of TachoSil® as a dural sealant improves the quality of craniotomy procedure and outcome in general compared with standard dural closure techniques in a controlled and randomized way. As a primary endpoint the investigators look at possible postoperative occurrence of CSF pads or leakages needing any kind of intervention until day 30 after the primary craniotomy. Furthermore, the investigators will look at other surgery-related complications and at pharmacoeconomic endpoints such as hospital stay or cost of the implant. Overall, the results of this study will provide important information on whether or not the adjunct of a relatively expensive implant on a routinely basis for the closure of elective craniotomies is safe and effective, or not.
To date, TachoSil® is often used in neurosurgery and other surgical disciplines in a non-standardized fashion also to prevent CSF leakage after dural closure. So far, adverse events directly related to the product have not been reported. Theoretically, any implant may be associated with a higher incidence of postoperative infections (e.g. epidural, subdural or subgaleal empyema). On the other hand, it is not known whether or not the application of TachoSil® on the dural suture may reduce CSF leakage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Neurosurgical indication for craniotomy and opening of dura to access cerebral structures/pathologies (discussed in the indication conference of board certified neurosurgeons at the University Hospital of Basel).
- •The list of pathologies includes:
- •primary or secondary benign/malignant brain tumors
- •aneurysms
- •arterious-venous malformations
- •cavernomas
- •pituitary adenomas
- •temporal lobectomy (epilepsy surgery)
- •longterm posttraumatic revisions.
排除标准
- •Presence of subdural empyema/abscess or any kind of infection affecting/infiltrating the dura mater
- •Emergency for trauma
- •Previous surgery on the same site
- •Cases, where water-tight dural suture is not possible (intraoperative exclusion decision)
- •Known hypersensitivity to TachoSil®
- •Participation in another study
- •Pregnancy
- •Inability to read and understand the participant's information
结局指标
主要结局
Occurence of CSF pad or leakage needing any kind of intervention.
时间窗: 30 days
次要结局
未报告次要终点
